Back    Zoom +    Zoom -
榮昌生物(09995.HK)RC148收到艾伯維6.5億美元首付款
Recommend
3
Positive
5
Negative
3
aacat by AASTOCKS
Open a new trading account to get NVDA share!
榮昌生物(09995.HK)宣布，已就RC148(一款由公司自主研發的新型靶向PD-1/VEGF雙特異性抗體藥物)的獨家授權許可協議從艾伯維(透過其控股公司)收到6.5億美元的首付款。目前雙方的合作進展順利。(ha/da)

AASTOCKS新聞
Switch to Auto-Translated Version
  • Remark
  • (1) HK Indices are real time
Home|RT Quote|Market|News|Indices
Feedback|Disclaimer
View: Mobile|Desktop
Lang: 繁|简|EN
Back To Top
Contact Us
Email: support@aastocks.com